Clinical Trial Update: Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating rivoceranib plus paclitaxel in people with Gastrointestinal Stromal Tumor is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Rivoceranib (rivoceranib)

Snippet

Sponsor: Asan Medical Center | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: RECRUITING